MedTrace Logo

Study on Optimal Treatment Strategy for Elderly Patients With High-risk Complex Aortic Valve Disease

NCT05044377 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 540

Last updated 2021-09-20

No results posted yet for this study

Summary

Aortic valve disease (AVD) is the most common and age-related mortality in elderly patients with valvular heart disease (VHD). Although transcatheter aortic valve replacement (TAVR) has been recommended at a higher level in foreign guidelines, there are still many high-risk and severe elderly patients with VHD who have not received effective treatment because of many complications and untimely medical treatment. Different from Europe and the United States, the majority of patients with bicuspid aortic valve are in China, and the calcification is more serious. The current clinical evaluation system and treatment guidelines can not be effectively applied to the high-risk and complex elderly patients. Therefore, the investigators should train and set up a valvular heart disease team, explore the technical difficulties of TAVR treatment in such patients, establish emergency TAVR operation mechanism, build a clinical evaluation system for high-risk and complex elderly patients with aortic valve disease in China, evaluate the curative effect periodically and further optimize the treatment strategy, so as to improve the quality of life and the meaning of life cycle of elderly patients with VHD in China Great significance.

Conditions

  • Aortic Valve Disease

Sponsors & Collaborators

  • Yongjian Wu

    lead OTHER_GOV

Principal Investigators

  • yongjian wu, doctor · Fuwai Hospital, National Center for Cardiovascular Diseases，Chinese Academy of Medical Sciences

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05044377 on ClinicalTrials.gov